ArticleInternational journal of clinical oncology2020
Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA.
Article in International journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis.International journal of colorectal disease · 2021Pooled it
- Serum total sialic acid and carcinoembryonic antigen as biomarkers in diagnosis and stratification of oral squamous cell carcinoma, oral submucous fibrosis, and periodontitis: a prospective cross-sectional analytical study.The Saudi dental journal · 2026Article
- Association between the preoperative Midkine (+)/CEA (+) level and poor prognosis in colorectal cancer patients.Surgery today · 2025Article
- Prognostic value of the preoperative prognostic nutritional and systemic immunoinflammatory indexes in patients with colorectal cancer.BMC cancer · 2025Article
- Prognostic significance of CEA reduction rate in patients with abnormally high preoperative CEA levels who underwent surgery for lung cancer.Journal of cardiothoracic surgery · 2024Article
- Preoperative Low Creatine Kinase as a Poor Prognostic Factor in Patients with Colorectal Cancer.Journal of gastrointestinal cancer · 2024Article
- Prognostic value of dynamic changes of pre- and post-operative tumor markers in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1.International journal of clinical oncology · 2024Article
- TIMP-2 as a predictive biomarker in 5-Fu-resistant colorectal cancer.Journal of cancer research and clinical oncology · 2023Article
- Robust Detection of Cancer Markers in Human Serums Using All-Dielectric Metasurface Biosensors.Biosensors · 2023Article
- Prognostic and diagnostic significance of preoperative Jumonji domain‑containing 6 antibodies in colorectal cancer.Oncology letters · 2023Article
- Prediction models of colorectal cancer prognosis incorporating perioperative longitudinal serum tumor markers: a retrospective longitudinal cohort study.BMC medicine · 2023Article
- Plasma protein changes reflect colorectal cancer development and associated inflammation.Frontiers in oncology · 2023Article
- Prognostic significance of combined α-fetoprotein and CA19-9 for hepatocellular carcinoma after hepatectomy.World journal of surgical oncology · 2022Article
- Comparison between a new assay system, ElecsysMolecular and clinical oncology · 2022Article
- Preoperative CRP(-)/CEA(-)/CA19-9(-)/non-T4 in Stage III Colorectal Cancer Is Favorable Risk for Recurrence.Journal of the anus, rectum and colon · 2022Article
- Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer.Surgery today · 2021Article
- Re-evaluating the clinical significance of serum p53 antibody levels in patients with oral cancer in Japanese clinical practice.Molecular and clinical oncology · 2021Article
- Prevalence of serum galectin-1 autoantibodies in seven types of cancer: A potential biomarker.Molecular and clinical oncology · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical impact of monitoring serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen in patients with colorectal cancer has not been fully evaluated.
methodsA total of 420 surgically treated stage II/III colorectal cancer patients were retrospectively analyzed. Among them, 101 patients developed disease recurrence. The prognostic impact of preoperative and recurrence levels of serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen status was evaluated.
resultsAlthough preoperative carcinoembryonic antigen- and carbohydrate antigen19-9-positive status was significantly associated with recurrence, preoperative serum p53 antibody levels were not. Among two marker combinations, carcinoembryonic antigen + serum p53 antibodies showed the highest positive rate at recurrence. Although carcinoembryonic antigen and carbohydrate antigen19-9 frequently converted from preoperative-negative status to positive status at recurrence, serum p53 antibodies converted to positive status in only one patient. Carcinoembryonic antigen- and carbohydrate antigen19-9-positive status were significant prognostic factors for overall survival after recurrence, but the presence of serum p53 antibodies at recurrence was not.
conclusionsPostoperative serum p53 antibody status should only be followed in patients with preoperative-positive status. Carcinoembryonic antigen and carbohydrate antigen19-9 should be followed even in preoperative-negative patients. Unlike carcinoembryonic antigen- and carbohydrate antigen19-9-positive status, serum p53 antibody-positive status as recurrence was not a poor prognostic indicator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.